Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04965038
Other study ID # 2021-000183-29
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date October 10, 2022
Est. completion date December 31, 2026

Study information

Verified date May 2024
Source University Hospital Tuebingen
Contact Sven Poli
Phone +49-7071-29-0
Email sven.poli@uni-tuebingen.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Non-arteritic, thromboembolic central retinal artery occlusion (CRAO) is an acute neurovascular-ophthalmological emergency which leads to severe and permanent vision loss; no evidence-based therapy does exist. Two recent meta-analyses indicate early intravenous thrombolysis to be beneficial in CRAO. Therefore, the REVISION randomized placebo-controlled interventional trial will investigate intravenous alteplase in CRAO as it is practiced in acute ischemic stroke, i.e. within 4.5 hours after symptom onset. The REVISION observational study will evaluate retinal changes on optical coherence tomography (OCT) in patients within 12 hours of CRAO onset, and the REVISION substudy, which will be conducted adjunct to either the interventional or the observational study, will evaluate the value of the retrobulbar spot sign for prediction of outcome and treatment response.


Description:

Non-arteritic, thromboembolic central retinal artery occlusion (CRAO) is an acute neurovascular-ophthalmological emergency which leads to severe and permanent vision loss in the affected eye in ~ 95% of cases. Despite a variety of widely practiced "conservative standard treatments", such as hemodilution, ocular massage, and paracentesis, there is no evidence-based therapy for non-arteritic CRAO. Animal models have proven a limited ischemic tolerance of the retina with irreversible damage occurring within only four hours after disruption of blood flow. This is why rapid reperfusion represents THE logical therapeutic approach. Two recent meta-analyses indicate early intravenous thrombolysis to be beneficial in CRAO. Therefore, the REVISION trial will investigate intravenous alteplase in CRAO as it is practiced in acute ischemic stroke, i.e. within 4.5 hours after symptom onset. Sequential evaluation by optical coherence tomography (OCT) will visualize dynamic ischemic changes of the retina during and after CRAO. The REVISION observational study will enroll patients within 12 hours of symptom onset and aims at comparing late time window retinal findings to early ischemic changes found in patients of the randomized REVISION interventional trial. Ultimately, OCT may become the preferred tool when it comes to assess retinal tissue viability in patients with an unknown CRAO onset (e.g. wake-up CRAO), and CRAO patients who present in an extended time window beyond 4.5 hours. The REVISION substudy, which will be conducted adjunct to either the interventional or the observational study, will evaluate the value of the retrobulbar spot sign for prediction of outcome and treatment response.


Recruitment information / eligibility

Status Recruiting
Enrollment 422
Est. completion date December 31, 2026
Est. primary completion date December 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Acute non-arteritic CRAO (i.e. sudden, painless monocular vision loss) = 12 hours after symptom onset confirmed by an experienced ophthalmologist through assessment of: BCVA, intraocular pressure, swinging flash light test (relative afferent pupil defect), slit-lamp biomicroscopy, fundoscopy, and OCT of the macula of both eyes* (*within the 4.5-hour time window: to be skipped if not feasible = 10 minutes; beyond the 4.5-hour time window: mandatory) - BCVA of LogMAR = 1.3 in the affected eye (functional blindness according to WHO ICD-11) - Reading must have been possible with the affected eye before CRAO (LogMAR = 0.5) - Neurological examination performed by an experienced stroke neurologist - Brain imaging as per local standard for acute retinal ischemia/stroke assessment, either cranial computed tomography (CT) or cranial magnetic resonance imaging (MRI) Exclusion Criteria: - Suspected giant cell arteritis - Other-than-CRAO cause of acute visual loss (e.g., retinal detachment, vitreous hemorrhage, acute glaucoma, acute optic neuritis) - BCVA of LogMAR < 1.3 or rapidly improving vision in the affected eye - Acute ischemic stroke with indication for on-label intravenous thrombolysis (IVT) - Any co-existing or terminal disease with anticipated life expectancy of < 3 months - Prior participation in the REVISION trial

Study Design


Intervention

Drug:
Alteplase
Intravenous thrombolysis with alteplase within 4.5 hours of symptom onset

Locations

Country Name City State
Germany University Hospital Tuebingen Tuebingen

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Tuebingen

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Exploratory Outcomes of the REVISION Interventional Study Optical coherence tomography/angiography (OCT/A) findings at screening, visit 2, 3, and 4 as prognostic biomarkers for prediction of time since CRAO onset, visual outcomes, and treatment response; to identify respective thresholds which are incompatible with a satisfactory IVT response and/or functional recovery 90 days
Other Exploratory Outcomes of the REVISION Observational Study Optical coherence tomography/angiography (OCT/A) findings at screening as prognostic biomarker for prediction of time since CRAO onset and visual outcomes, and to compare extended time window results to those of interventional study participants. 1 day
Other Exploratory Outcomes of the Retrobulbar Spot Sign Substudy To investigate the retrobular spot sign on transorbital ultrasound at visits 2 and 3 as prognostic biomarker for prediction of treatment response and visual outcomes; to compare central retinal artery recanalization assessment with transorbital ultrasound with that using optical coherence tomography/angiography (OCT/A) of the optic nerve head and the macula, and fluorescein angiography 30 days
Primary Functional recovery at visit 3 Functional recovery to best corrected visual acuity of logarithm of the minimum angle of resolution = 0.5 in the affected eye, which corresponds to normal to mild vision impairment (intention-to-treat analysis). 30 days
Secondary best corrected visual acuity (BCVA) at visits 2, 3, and 4 Functional recovery to best corrected visual acuity of logarithm of the minimum angle of resolution = 0.5 in the affected eye, which corresponds to normal to mild vision impairment (intention-to-treat and per-protocol analyses). 90 days
Secondary Shift in visual outcome categories at visits 2, 3, and 4 Shift in visual outcome categories: normal vision (logarithm of the minimum angle of resolution (LogMAR) = 0), mild vision impairment (LogMAR > 0 and = 0.5), moderate vision impairment (LogMAR > 0.5 and = 1.0), severe vision impairment (LogMAR > 1.0 and = 1.3), counting fingers (LogMAR > 1.3 and = counting fingers), hand motion or light perception, and no light perception. 90 days
Secondary Dichotomized analysis of visual outcome at visits 2, 3, and 4 Dichotomized analysis of visual outcome: 'normal vision to moderate vision impairment' vs. 'severe vision impairment or functional blindness' and 'normal vision to severe vision impairment' vs. 'functional blindness'. 90 days
Secondary Visual field at visits 3 and 4 Kinetic visual field using III4e mark 90 days
Secondary Central retinal artery recanalization at visits 2, 3, and 4 Central retinal artery recanalization assessed using optical coherence tomography angiography (OCTA) of the optic nerve head and the macula. 90 days
Secondary Retinal arterial perfusion at visits 3 and 4 Retinal arterial perfusion assessed using fluorescein angiography. 90 days
Secondary National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) at visits 3 and 4 NEI-VFQ-25 for assessment of relevant visual impairment 90 days
Secondary National Institutes of Health Stroke Scale (NIHSS) score at visit 2 NIHSS for assessment of neurological deficits due to ischemic stroke or intracranial hemorrhage 72 hours
Secondary Modified Rankin Scale (mRS) score at visits 3 and 4 Dichotomized analysis and shift analyses of mRS (categories 0 - 1 (excellent outcome) vs. 2 - 6, 0 - 2 (functional independence) vs. 3 - 6, 0 - 3 (walking) vs. 4 - 6, and 0 - 4 vs. 5 - 6 (bedridden or death), and shift analysis) 90 days
Secondary Fresh ischemic lesions on cranial magnetic resonance imaging (MRI) at visit 2 Fraction of patients with and number of acute ischemic lesions on follow-up diffusion-weighted cranial MRI 72 hours
Secondary Death at visits 3 and 4 All-cause and stroke-related death 90 days
Secondary Any intracranial hemorrhage (ICH) at visit 2 Any ICH (except microhemorrhages) on follow-up magnetic resonance imaging; in case of missing follow-up brain imaging due to premature death, ICH will be replaced by "ICH or death without repeat scan") 72 hours
Secondary Symptomatic intracranial hemorrhage (ICH) until visit 2 Symptomatic ICH (as per ECASS III and Heidelberg bleeding classification) until follow-up magnetic resonance imaging; in case of missing follow-up brain imaging due to premature death, symptomatic ICH will be replaced by "symptomatic ICH or death without repeat scan") 72 hours
Secondary Intraocular hemorrhage in the affected eye at visit 2 Intraocular hemorrhage in the affected eye 72 hours
Secondary Major bleeding until visit 2 Major bleeding, defined as clinically overt bleeding associated with at least one of the following features: decrease in hemoglobin levels of = 2 g/dL over 24 hours, bleeding requiring transfusion of = 2 units of packed red cells, bleeding at a critical site (i.e., intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal), or bleeding resulting in the death of the patient 72 hours
Secondary Retinal neovascularization requiring therapy at visit 3 and 4 Retinal neovascularization requiring therapy 90 days
Secondary (Serious) adverse events ((S)AE) AE until visit 2, serious AE and AE of special interest until visit 3 and 4 90 days
See also
  Status Clinical Trial Phase
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Recruiting NCT04526951 - TENecteplase in Central Retinal Artery Occlusion Stuy (TenCRAOS) Phase 3
Recruiting NCT01348633 - Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye N/A
Completed NCT03197194 - A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion Phase 3
Recruiting NCT05562284 - Safety and Efficacy After Selective Intra-arterial Thrombolysis for Central Retinal Artery Occlusion N/A
Completed NCT05739487 - Changes of Visual Field Defects After IAT for CRAO
Completed NCT03049514 - Study of Arterial Recanalization of the Central Retinal Artery Occlusions
Terminated NCT00802698 - The Effect of Transcorneal Stimulation in Cases of Central Retinal Artery Occlusion Using a New Waveform N/A
Recruiting NCT06178055 - A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arthritic Central Retinal Artery Occlusion (CRAO) Phase 2